Retatrutide dosage in the clinical trials — what was administered, to whom, and by what schedule.

The short version

Retatrutide has been studied at doses ranging from 0.5 mg to 12 mg, given by subcutaneous injection (an injection into the fatty tissue just under the skin) once per week. All trials used a gradual dose escalation schedule — starting low and stepping up over weeks — to manage stomach-related side effects.

This page describes what the clinical trials studied and how they were designed. It is not dosing guidance. Retatrutide is an investigational compound — it is not approved for prescription use anywhere as of 2026, and there is no approved dosing schedule. The figures here are study-design facts from published protocols. Retatrutide research covers the efficacy and safety findings in full.

Retatrutide dosage

Across the published clinical program, once-weekly subcutaneous injection has been the consistent route.

Phase 1b (n=72, type 2 diabetes, 12 weeks): Cohorts received 0.5 mg, 1.5 mg, 3 mg, 3/6 mg, and 3/6/9/12 mg in escalating weekly steps. This trial established the pharmacokinetic profile, tolerability, and dose escalation feasibility ^[4].

Phase 2 obesity (n=338, 48 weeks): Fixed-dose arms of 1, 4, 8, and 12 mg once weekly, administered after a lead-in dose-escalation period. The 12 mg arm produced the −24.2% mean body-weight change at 48 weeks ^[1].

Phase 2 type 2 diabetes (n=281, 36 weeks): Starting dose 0.5 mg, escalating stepwise to a maximum of 12 mg over the trial. HbA1c −2.02% and body weight −16.94% at 36 weeks for 12 mg ^[2].

Phase 3 TRANSCEND-T2D-1 (n=537, type 2 diabetes, 40 weeks): Retatrutide 12 mg with structured escalation. HbA1c −1.94%, body weight −15.3% versus placebo ^[12].

In every trial, dose escalation was a protocol requirement — not optional — because the GI adverse event profile is dose-dependent. Rapid titration to 12 mg without the escalation schedule used in the trials would not replicate the tolerability profile those trials documented.

Half-life and pharmacokinetics

The Phase 1b trial measured a half-life of approximately 6 days for retatrutide ^[4]. This is the pharmacological basis for once-weekly dosing: after a single injection, the drug concentration falls by half over roughly 6 days, reaching steady-state after approximately 4–5 weeks of weekly administration.

The extended half-life is achieved by acylation — attachment of a C20 fatty-diacid chain that binds to albumin (a carrier protein abundant in blood), which slows renal clearance and prolongs circulation time.

Peak plasma concentration (Cmax) is reached several days after injection; the flat concentration-time profile from weekly dosing is what enables consistent weekly suppression of appetite and GI hormonal effects rather than the pulse-and-trough pattern of shorter-acting molecules.

How to reconstitute retatrutide

There is no approved formulation, reconstitution protocol, or storage standard for retatrutide outside clinical trials. The clinical trials administered pre-formulated investigational product prepared under controlled pharmaceutical conditions — not a lyophilized (freeze-dried) powder that trial participants reconstituted themselves.

The question of "how to reconstitute retatrutide" arises because gray-market research-labeled products are sometimes sold as lyophilized vials. This site does not provide reconstitution instructions for an unapproved compound of unverified identity and purity. Vials obtained outside clinical trials cannot be confirmed to contain authentic retatrutide, and no reconstitution standard derived from clinical-trial protocols exists for such products — those protocols specified pharmaceutical-grade pre-filled syringes, not lyophilized powder.

The relevant caution: if the vial's contents are not authenticated retatrutide, any reconstitution method is irrelevant to safety or dosing.

The Retatrutide research page covers what the trials actually administered.

Retatrutide cost

Retatrutide does not have a commercial price because it is not a marketed drug as of 2026. It does not have an approved indication, a labeled dosage form, or a pharmacy-dispensed supply.

A gray market exists for research-labeled retatrutide. Prices in those channels reflect the cost of producing unverified peptide material — not the cost of an approved pharmaceutical with identity, purity, and sterility guarantees.

Once approved — if and when that occurs — pricing will be set through Eli Lilly's standard commercial process, potentially subject to payer negotiations. Precedents from the broader incretin-drug class suggest monthly costs in the hundreds to low thousands of dollars range for uninsured patients, though this is speculative and no pricing has been announced for retatrutide specifically. This site tracks the trial literature, not commercial projections.

Stability and storage context

The clinical trials used pharmaceutical-grade, pre-formulated investigational product under controlled storage conditions (typically 2–8°C refrigeration with defined shelf life) — conditions that guarantee peptide integrity. No approved stability data or storage guidance exists for any non-trial preparation of retatrutide.

For reference: peptides in the incretin class are generally susceptible to temperature extremes, repeated freeze-thaw cycles, and exposure to light or moisture, all of which can cause degradation of the active amino-acid sequence. Whether any given vial of gray-market material contains intact retatrutide at the stated concentration cannot be determined without mass spectrometry or HPLC analysis — neither of which is available to a research-use purchaser.